[
  {
    "ts": "2025-10-17T21:50:03+00:00",
    "headline": "Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know",
    "summary": "The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $416.81, representing a +2.01% change from its previous close.",
    "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-outpaces-stock-215003864.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "d2708d15-83c2-3cb7-b8cf-a0bc495c6fec",
      "content": {
        "id": "d2708d15-83c2-3cb7-b8cf-a0bc495c6fec",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know",
        "description": "",
        "summary": "The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $416.81, representing a +2.01% change from its previous close.",
        "pubDate": "2025-10-17T21:50:03Z",
        "displayTime": "2025-10-17T21:50:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/21b1f011539d3e31c28282071d344177",
          "originalWidth": 900,
          "originalHeight": 598,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2yFNHFE.NEelN3EcxccP6Q--~B/aD01OTg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/21b1f011539d3e31c28282071d344177.cf.webp",
              "width": 900,
              "height": 598,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tL0vRMsfrFLR6L27GP3atA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/21b1f011539d3e31c28282071d344177.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-outpaces-stock-215003864.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-outpaces-stock-215003864.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^IXIC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-17T13:04:00+00:00",
    "headline": "Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week",
    "summary": "BOSTON, October 17, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential",
    "url": "https://finance.yahoo.com/news/vertex-announces-progress-povetacicept-development-130400873.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "e96d6e06-14dd-3dcf-9741-ccc2f09b28a7",
      "content": {
        "id": "e96d6e06-14dd-3dcf-9741-ccc2f09b28a7",
        "contentType": "STORY",
        "title": "Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week",
        "description": "",
        "summary": "BOSTON, October 17, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential",
        "pubDate": "2025-10-17T13:04:00Z",
        "displayTime": "2025-10-17T13:04:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/00facd1a44082df527140386cf9e0918",
          "originalWidth": 480,
          "originalHeight": 252,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7wINIzBBr0RO7vVJ.9u8zg--~B/aD0yNTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/00facd1a44082df527140386cf9e0918.cf.webp",
              "width": 480,
              "height": 252,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/d0lRAX9g5emOS_nWG0BS5g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/00facd1a44082df527140386cf9e0918.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-announces-progress-povetacicept-development-130400873.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-announces-progress-povetacicept-development-130400873.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-17T11:32:50+00:00",
    "headline": "Vertex Pharmaceuticals: Commercial Pipeline Is Stronger Than What The Market Thinks",
    "summary": "Vertex is still growing fast but the market has given investors another chance to fill up on shares.",
    "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-commercial-pipeline-stronger-113250728.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "e6db62d0-dc4a-3631-9c88-69991066cf27",
      "content": {
        "id": "e6db62d0-dc4a-3631-9c88-69991066cf27",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals: Commercial Pipeline Is Stronger Than What The Market Thinks",
        "description": "",
        "summary": "Vertex is still growing fast but the market has given investors another chance to fill up on shares.",
        "pubDate": "2025-10-17T11:32:50Z",
        "displayTime": "2025-10-17T11:32:50Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/9ad9baa872cd36658a2db63b8eb4608a",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yDsKaqARbNgha28_qyzHaQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/9ad9baa872cd36658a2db63b8eb4608a.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qO.qSuA3dSl8cTtC0M9sxQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/9ad9baa872cd36658a2db63b8eb4608a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-commercial-pipeline-stronger-113250728.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-commercial-pipeline-stronger-113250728.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]